Refine by
Life Threatening Disease Articles & Analysis: Older
107 news found
Bronchiectasis APIs for Respiratory Health In respiratory health, Protheragen-ING brings APIs like umeclidinium bromide and vilanterol trifenatate for bronchiectasis, a chronic disease in which bronchi are widened and mucus is not cleared, which results in infection. Bronchodilators and other medicines whose efficacy in clearing the airways and clearing mucus offers relief to ...
In humans, 88 human adenoviruses have been identified in seven populations (A through G) and more than 50 different adenovirus serotypes have been identified, causing a wide range of diseases from mild respiratory infections in young children to life-threatening multi-organ disease in people with compromised immune systems. ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. ...
When approved, XPOVIO® will offer an important novel treatment option in the care of patients with these life threatening diseases in Macau,China, Malaysia and Thailand.” “Antengene is executing on our strategy to bring transformative medicines to patients around the world. ...
He has led the Company in creating a diverse clinical-stage portfolio of engineered antibodies and cytokines for the treatment of life-threatening and debilitating diseases, and has established alliances with leading biopharmaceutical companies that have resulted in three marketed drugs. ...
There remains an unmet need to extend survival for patients with these life-threatening diseases and XPOVIO® presents Taiwan physicians and patients with a new novel addition to existing therapies. ...
A positive study would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit of doxorubicin ...
The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care diseases and community medical threats, ...
This is a significant accomplishment for CDx which underscores the clinical value of WATS3D and its continued role in preempting this potentially life-threatening disease, one patient at a ...
Because pre-clinical research and emerging clinical data support the potential for OKN-007 in this population and the life-threatening nature of malignant gliomas including DIPG, Oblato is making OKN-007 available to qualified physicians through the iEAP. ...
ByxCures
Empirical Spine, Inc., a company developing advanced solutions for the surgical treatment of spinal disorders, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its LimiFlex™ Paraspinous Tension Band. In doing so, the FDA has determined that LimiFlex™ holds the potential to offer significant advantages over ...
The FDA Breakthrough Devices Program expedites the development, assessment and review process for certain medical devices that provide for more effective treatment options for patients with life-threatening or irreversibly debilitating diseases or conditions. ...
In the ongoing Phase 2 study evaluating posoleucel for the prevention of clinically significant infections and disease caused by AdV, BKV, CMV, EBV, HHV-6 and JCV in allo-HCT patients, no patients developed BKV-associated HC. ...
ByKalaris
High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. ...
Infant Bacterial Therapeutics AB (publ) (IBT) is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world’s first approved probiotical ...
Historic Leuven, a small city in central Belgium, is the next stop on our virtual tour of KLA’s global locations. The 9th century town, dotted with spectacular medieval and Renaissance architecture, has the country’s oldest university – and a major technology hub where, for 40 years, KLA’s ICOS division has been helping to transform our future. Since it’s spin-out ...
“It’s an honor to join Vertex, a company focused on serial innovation with an industry-leading track record of discovering, developing and commercializing transformative medicines to treat serious diseases. It is particularly exciting to join at such a pivotal time, when the company is in the process of transforming the treatment of multiple serious ...
These buildings represent a further significant investment in our unique R&D strategy, to transform the lives of people with serious diseases, like sickle cell disease and type 1 diabetes, using cutting-edge genetic and cell-based ...